Clinical Trials Arena on MSN
Compass stock heads north on psychedelic’s Phase III TRD success
Compass will now seek approval for COMP360, which could become the first classic psychedelic to gain the FDA’s blessing.
NEW YORK, Jan. 9, 2026 /PRNewswire/ --Compass, Inc. (NYSE: COMP) announces the completion of its all-stock combination with Anywhere Real Estate Inc. Following the merger, the two companies are coming ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results